This guidance updates and replaces NICE's technology appraisal guidance 212 on bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment ...

The efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in relation to tumor-infiltrating lymphocytes: Histological assessment of CD8+ T cell spatial features as predictive ...

Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy is available on the NHS. It is a possible first- or second-line treatment for metastatic colorectal cancer in adults, ...

Veteran ophthalmology leader with 35+ years of market expertise selected as exclusive Switzerland partner Mediconsult to seek Marketing Authorization and lead commercialization activities for ...

Amgen is pushing back against a request from US regulators to remove a drug for a rare autoimmune disease from the market, even as European regulators conduct a separate inquiry into data used to ...